A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects
Latest Information Update: 21 Oct 2024
At a glance
- Drugs APHD-012 (Primary)
- Indications Obesity
- Focus Proof of concept; Therapeutic Use
- Sponsors Aphaia Pharma
Most Recent Events
- 16 Oct 2024 Planned End Date changed from 30 Mar 2024 to 11 Nov 2024.
- 16 Oct 2024 Planned primary completion date changed from 30 Mar 2024 to 11 Nov 2024.
- 16 Oct 2024 Status changed from recruiting to active, no longer recruiting.